HPTP-Beta inhibitors
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
1. A compound of formula:
wherein:
Aryl 1 is 4-phenylsulfamic acid;
Aryl 2 is
wherein:
R e is H;
R f heteroaryl that is substituted or unsubstituted;
X is methylene;
L is alkylene, alkenylene, or alkynylene, any of which is substituted or unsubstituted, or together with the nitrogen atom to which L is bound forms an amide linkage, a carbamate linkage, a ureido linkage, or a sulfonamide linkage, or a chemical bond;
R a is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, any of which is substituted or unsubstituted, or H;
R b is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl, any of which is substituted or unsubstituted, or H;
R c is alkyl which is substituted or unsubstituted, or H; and
R d is alkyl which is substituted or unsubstituted, or H,
or a pharmaceutically-acceptable salt, tautomer, or zwitterion thereof.
2. The compound of claim 1 , wherein:
L together with the nitrogen atom to which L is bound forms a carbamate linkage;
R a is alkyl, which is substituted or unsubstituted;
R b is arylalkyl, which is substituted or unsubstituted;
R c is H; and
R d is H.
3. The compound of claim 1 , wherein the compound is: